Loading clinical trials...

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma | Clinical Trials | Clareo Health

COMPLETEDNCT03568929

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma

The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).

Lead sponsor: Gilead Sciences•88 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment257

Start dateMay 2018

Last updatedNov 19, 2021

Condition

Follicular Non-Hodgkin's Lymphoma Refractory

Locations shown

Ziekenhuis Netwerk Antwerpen Stuivenberg Hospital

Antwerp

Centre Hospitalier Universitaire d'Amiens (CHU d'Amiens) - Hopital Nord

Amiens

Centre Hospitalier Bourg-en-Bresse Fleyriat

Bourg-en-Bresse

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 19, 2021Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions